GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Raptor Pharmaceutical Corp (NAS:RPTP) » Definitions » Cyclically Adjusted Revenue per Share

Raptor Pharmaceutical (Raptor Pharmaceutical) Cyclically Adjusted Revenue per Share : $0.00 (As of Jun. 2016)


View and export this data going back to 1999. Start your Free Trial

What is Raptor Pharmaceutical Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Raptor Pharmaceutical's adjusted revenue per share for the three months ended in Jun. 2016 was $0.375. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Jun. 2016.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-05), Raptor Pharmaceutical's current stock price is $9.00. Raptor Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2016 was $0.00. Raptor Pharmaceutical's Cyclically Adjusted PS Ratio of today is .


Raptor Pharmaceutical Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Raptor Pharmaceutical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raptor Pharmaceutical Cyclically Adjusted Revenue per Share Chart

Raptor Pharmaceutical Annual Data
Trend Dec06 Dec07 Dec08 Aug09 Aug10 Aug11 Aug12 Dec13 Dec14 Dec15
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Raptor Pharmaceutical Quarterly Data
Aug11 Nov11 Feb12 May12 Aug12 Nov12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Raptor Pharmaceutical's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Raptor Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Raptor Pharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Raptor Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Raptor Pharmaceutical's Cyclically Adjusted PS Ratio falls into.



Raptor Pharmaceutical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Raptor Pharmaceutical's adjusted Revenue per Share data for the three months ended in Jun. 2016 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2016 (Change)*Current CPI (Jun. 2016)
=0.375/101.6881*101.6881
=0.375

Current CPI (Jun. 2016) = 101.6881.

Raptor Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200606 76.969 85.606 91.429
200609 76.969 85.606 91.429
200612 13.533 85.142 16.163
200703 2.668 86.640 3.131
200706 2.666 87.906 3.084
200709 2.660 87.964 3.075
200712 2.663 88.616 3.056
200803 2.210 90.090 2.495
200806 1.309 92.320 1.442
200809 1.319 92.307 1.453
200812 1.717 88.697 1.968
200903 0.000 89.744 0.000
200906 0.298 91.003 0.333
200911 0.000 91.272 0.000
201002 0.000 91.445 0.000
201005 0.000 92.052 0.000
201008 0.000 92.108 0.000
201011 0.000 92.315 0.000
201102 0.000 93.373 0.000
201105 0.000 95.337 0.000
201108 0.000 95.582 0.000
201111 0.000 95.449 0.000
201202 0.000 96.053 0.000
201205 0.000 96.961 0.000
201208 0.000 97.199 0.000
201211 0.000 97.133 0.000
201303 0.000 98.209 0.000
201306 0.000 98.518 0.000
201309 0.110 98.790 0.113
201312 0.177 98.326 0.183
201403 0.195 99.695 0.199
201406 0.260 100.560 0.263
201409 0.378 100.428 0.383
201412 0.273 99.070 0.280
201503 0.296 99.621 0.302
201506 0.292 100.684 0.295
201509 0.317 100.392 0.321
201512 0.313 99.792 0.319
201603 0.322 100.470 0.326
201606 0.375 101.688 0.375

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Raptor Pharmaceutical  (NAS:RPTP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Raptor Pharmaceutical Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Raptor Pharmaceutical's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Raptor Pharmaceutical (Raptor Pharmaceutical) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Therapeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. It is a biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company's product PROCYSBI cysteamine bitartrate, delayed-release capsules received marketing approval from the U.S. Food and Drug Administration on April 30, 2013 for the management of nephropathic cystinosis in adults and children six years and older. The European equivalent, PROCYSBI gastro-resistant hard capsules of cysteamine, received marketing authorization on September 6, 2013 from the European Commission, as an orphan medicinal product for the management of nephropathic cystinosis for marketing in the European Union. PROCYSBI received 7 years and 10 years of market exclusivity as an orphan drug in the U.S. and the EU, respectively. PROCYSBI is an approved therapy for the management of nephropathic cystinosis, a rare, life-threatening metabolic lysosomal storage disorder that causes the rapid, toxic accumulation of cystine in all cells, tissues and organs in the body. PROCYSBI capsules contain cysteamine bitartrate in the form of microspheronized beads that are individually coated to create delayed and extended-release properties, allowing patients to maintain consistent therapeutic systemic drug levels over a 12-hour dosing period. Cysteamine is a molecule generated in the cell during the metabolism of cysteine. The Company's pipeline products include; its proprietary delayed-release form of cysteamine, or RP103. The Company currently has product candidates in clinical development designed to potentially treat Huntington's disease, Non-alcoholic fatty liver disease, Leigh syndrome and other mitochondrial disorders and aldehyde dehydrogenase deficiency. The Company's preclinical programs are based upon bioengineered novel drug candidates that are designed to target cancer and other diseases. Its other clinical-stage product candidates include: Convivia its proprietary oral formulation of 4-methylpyrazole, for the potential management of acetaldehyde toxicity due to alcohol consumption by individuals with aldehyde dehydrogenase, or ALDH2, deficiency, an inherited metabolic disorder. With respect to any of the Company's product candidates for which it obtain FDA approval, it will be subject to ongoing FDA obligations and continued regulatory review, which may result in additional expense.
Executives
Raymond Anderson director C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Krishna R Polu officer: Chief Medical Officer C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Michael P Smith officer: Chief Financial Officer 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Georges Gemayel director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Llew Keltner director 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Christopher M Starr director C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
David Happel officer: Chief Commercial Officer 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Julie Smith director, officer: President and CEO C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Erich Sager director 9 COMMERCIAL BLVD., SUITE 200, NOVATO CA 94949
Georgia Erbez officer: Chief Financial Officer 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Vijay B Samant director 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Patrice Rioux other: CMO, Raptor Therapeutics C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091

Raptor Pharmaceutical (Raptor Pharmaceutical) Headlines

No Headlines